Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC ：Prospective Study

Conditions:   Carcinoma;   Non-Small-Cell Lung Cancer;   Adenocarcinoma Interventions:   Drug: Elemene plus First-generation EGFR-TKIs;   Drug: First-generation EGFR-TKIs Sponsors:   Tian Xie;   LinkDoc Technology (Beijing) Co. Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials